丰原药业(000153) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was CNY 1,120,669,012.93, a decrease of 7.08% compared to CNY 1,206,114,496.19 in the same period last year[4] - Net profit attributable to shareholders was CNY 47,010,852.21, reflecting a 2.14% increase from CNY 46,024,429.74 year-on-year[4] - The net profit after deducting non-recurring gains and losses was CNY 41,674,569.58, up 4.96% from CNY 39,706,065.28 in the previous year[4] - Total operating revenue for Q1 2024 was CNY 1,120,669,012.93, a decrease of 7.1% from CNY 1,206,114,496.19 in the same period last year[16] - Net profit for Q1 2024 was CNY 46,363,541.16, reflecting a 1.6% increase from CNY 45,642,875.16 in the previous year[17] - Earnings per share (EPS) for Q1 2024 was CNY 0.1416, up from CNY 0.1386 in Q1 2023, indicating a growth of 2.2%[18] Cash Flow - The net cash flow from operating activities decreased by 21.29% to CNY 15,777,633.43 from CNY 20,045,680.47 in the same period last year[4] - Cash flow from operating activities totaled CNY 977,470,684.37, a decrease of 5.5% compared to CNY 1,034,532,225.52 in the same quarter last year[19] - The net cash flow from operating activities was 15,777,633.43 CNY, a decrease of 21.2% compared to 20,045,680.47 CNY in the previous year[21] - The total cash outflow from investing activities was 114,711,320.33 CNY, significantly higher than 28,798,232.70 CNY in the same period last year[21] - The net cash flow from financing activities was 81,911,173.50 CNY, a recovery from a negative cash flow of -138,883,346.02 CNY in the previous year[21] - The total cash and cash equivalents at the end of the period were 273,739,417.10 CNY, down from 344,672,700.29 CNY at the beginning of the period[21] Assets and Liabilities - Total assets increased by 7.10% to CNY 4,703,099,357.93 compared to CNY 4,391,320,148.20 at the end of the previous year[4] - Total current assets increased to ¥2,124,341,394.28 from ¥1,902,911,251.25, reflecting a growth of approximately 11.65%[13] - Total liabilities increased to CNY 2,732,348,255.43, up from CNY 2,472,494,405.67, representing an increase of 10.5%[17] - Current liabilities increased to ¥2,252,977,334.26 from ¥2,013,636,055.35, reflecting a rise of about 11.85%[14] - Short-term borrowings increased to ¥433,731,902.78 from ¥344,286,277.78, an increase of approximately 26.1%[14] Shareholder Information - Total number of common shareholders at the end of the reporting period is 40,268[10] - The largest shareholder, Anhui Wuwei Pharmaceutical Factory, holds 10.79% of shares, totaling 35,842,137 shares[10] - Shareholders' equity attributable to the parent company rose by 2.67% to CNY 1,939,900,305.48 from CNY 1,889,409,585.59 at the end of last year[4] - Total equity attributable to shareholders of the parent company rose to CNY 1,939,900,305.48, compared to CNY 1,889,409,585.59, an increase of 2.7%[17] Research and Development - Research and development expenses decreased by 48.14% to CNY 12,983,646.70 from CNY 25,035,890.83 in the previous year[8] - Research and development expenses were CNY 12,983,646.70, significantly reduced from CNY 25,035,890.83 in Q1 2023, marking a decrease of 48.2%[17] Other Income and Expenses - The company reported a significant increase of 153.81% in other income, totaling CNY 18,765,531.63, primarily due to increased government subsidies[8] - Total operating costs decreased to CNY 1,058,729,460.12, down 7.6% from CNY 1,145,309,254.54 year-on-year[16] - The company reported a decrease in sales expenses to CNY 159,552,828.87, down 20.4% from CNY 200,444,348.75 in the previous year[17] Inventory and Receivables - Accounts receivable rose to ¥1,025,692,442.00 from ¥791,523,059.81, an increase of about 29.5%[13] - Inventory decreased slightly to ¥569,163,882.62 from ¥573,578,704.53, a decline of about 0.77%[13] Audit Status - The company has not yet audited the first quarter report for 2024[22]